PET引导剂量提升治疗III期非小细胞肺癌:一项随机临床试验
2年局部区域失败率标准组27.5% vs 剂量提升组18.4%(P=.13),OS和PFS无差异,≥3级毒性25% vs 37%(P=.26)。结论:PET引导剂量提升可行但未显著改善局部控制或生存。
要点
- PET引导剂量提升至FDG高摄取亚区最高85 Gy未显著降低2年局部区域失败(27.5% vs 18.4%,P=.13)。
- 两组2年OS(72.5% vs 73.7%,P=.91)和PFS(52.5% vs 57.9%,P=.74)无差异。
- 剂量提升组≥3级治疗相关毒性37% vs 标准组25%(P=.26),发生1例5级肺出血。
核心结论
- 代谢自适应PET引导放疗剂量提升在巩固免疫治疗背景下可行,局部区域失败率数值上较低但未显著改善局部控制或生存。
主要发现
- 2年局部区域失败率标准组27.5% vs 剂量提升组18.4%(P=.13)。
- 2年OS标准组72.5% vs 剂量提升组73.7%(P=.91),2年PFS 52.5% vs 57.9%(P=.74)。
- ≥3级治疗相关毒性标准组25% vs 剂量提升组37%(P=.26),剂量提升组发生1例5级肺出血。
- 生活质量两组无差异。
关键数值与推荐
- 标准放疗处方剂量60 Gy/30次,剂量提升组对FDG高摄取亚区整合boost最高85 Gy/30次,中位处方boost剂量75 Gy。
- 入组要求可达到boost剂量至少65 Gy,允许2018年后使用巩固durvalumab(76%患者接受)。
临床怎么用
- 在巩固免疫治疗时代,PET引导的选择性剂量提升可行,但当前证据未显示显著局部控制或生存获益,需更大样本研究确定临床意义。
局限性
- 事件率低于预期可能限制了统计效能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Uniform radiation dose escalation has not improved outcomes in locally advanced non-small cell lung cancer (NSCLC), and locoregional failure remains common despite multimodal therapy. We evaluated whether fluorodeoxyglucose positron emission tomography (FDG-PET)-guided dose escalation to metabolically active tumor subvolumes reduces locoregional failure compared with standard chemoradiation. METHODS AND MATERIALS: PET-BOOST was a multi-institutional, open-label, phase 2 randomized trial conducted at 7 Canadian centers (January 2017-May 2022). Eligible patients had inoperable, FDG-avid stage IIIA/IIIB NSCLC and an achievable boost dose of at least 65 Gy. Patients were randomized 1:1 to standard chemoradiation with 60 Gy in 30 fractions or metabolically adaptive radiotherapy with an integrated boost to FDG-avid subvolumes to a maximum of 85 Gy in 30 fractions. Concurrent platinum-based chemotherapy was planned, and consolidation durvalumab was permitted after 2018. The primary endpoint was 2-year locoregional failure; secondary endpoints included overall survival (OS), progression-free survival (PFS), grade ≥3 treatment-related toxicity, and quality of life (QOL). RESULTS: Seventy-eight patients were randomized: 40 to standard radiotherapy and 38 to dose escalation, with a median follow-up of 5.0 years. Median age was 64.4 years; 53% were male, 62% had stage IIIA disease, and 76% received consolidation durvalumab. Median prescription boost dose was 75 Gy. Two-year locoregional failure was 27.5% with standard radiotherapy versus 18.4% with dose escalation (P=.13). Two-year OS (72.5% vs. 73.7%; P=.91) and PFS (52.5% vs. 57.9%; P=.74) did not differ between arms. Grade ≥3 treatment-related toxicities occurred in 25% versus 37% of patients (P=.26), with one grade 5 pulmonary hemorrhage in the dose-escalation arm. QOL did not differ between arms. CONCLUSIONS: Metabolically adaptive PET-guided radiotherapy dose escalation was feasible in the context of consolidation immunotherapy and resulted in a numerically lower rate of locoregional failure, but did not significantly improve locoregional control or survival. The lower-than-anticipated event rate may have limited statistical power, and larger studies would be required to determine whether selective dose escalation provides a clinically meaningful improvement in locoregional control.
引用
- Raman S, Bissonnette JP, Palma DA, et al. PET-Guided Dose Escalation for Stage III Non-Small Cell Lung Cancer: A Randomized Clinical Trial. Int J Radiat Oncol Biol Phys. 2026. PMID: 42918583. doi:10.1016/j.ijrobp.2026.10.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。